Home / Going-concern warnings / SANGAMO THERAPEUTICS, INC
Filed 2025-05-12 路 Form 10-Q 路 Accession 0001628280-25-024650 nano
Price before filing: $0.7 (2025-05-09 close, split/dividend-adjusted)
Market cap at flag: n/a 路 Latest: $45.7M (2026-10-16)
| Window | SGMOQ | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -25.7% | +6.6% | -32.3% | 2025-06-11 |
| 90 days | -37.1% | +13.0% | -50.2% | 2025-08-11 |
| 180 days | -27.1% | +21.4% | -48.6% | 2025-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"Our history of significant losses, negative cash flows from operations, limited liquidity resources currently on hand and dependence on our ability to obtain substantial additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in..."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.